Peptide Graded

Fragment 176-191

Is Fragment 176-191 safe?

Only the developer's reports; no repeated-use data

CAnimal and cell studiesNot approvedas of 2026-10-26

The developer's trials reportedly found AOD9604 well tolerated. In rodents it did not cause the insulin resistance or raised blood sugar that intact growth hormone does. That is all the safety data there is. Nobody has tested the injectable products sold online for purity. There are no data on repeated injections under the skin in people. 234

Read the full Fragment 176-191 page

More on Fragment 176-191

Citations

  1. Wu and Ng 1993, Biochemistry and Molecular Biology International: antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone pubmed.ncbi.nlm.nih.gov
  2. Ng 2000, Hormone Research: metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone pubmed.ncbi.nlm.nih.gov
  3. Heffernan 2001, International Journal of Obesity: increase of fat oxidation and weight loss in obese mice with growth hormone or a modified C-terminal fragment pubmed.ncbi.nlm.nih.gov
  4. Kakkar and Dahiya 2013, Current Cardiology Reviews: obesity pharmacotherapy, current perspectives and future directions pubmed.ncbi.nlm.nih.gov
  5. Ng 2000, Hormone Research: metabolic studies of AOD9604 (DOI record) doi.org
  6. Stier 2013, Journal of Endocrinology and Metabolism: safety and tolerability of the hexadecapeptide AOD9604 in humans doi.org

Reference information only, not medical advice. Drawn from the Fragment 176-191 article, fact-checked against the cited sources. No dosing anywhere on this site.